Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q3 2026, worth $2.18M in total; no superinvestor holds it.
13F holders, Q3 2026
Institutional positions in Indaptus Therapeutics, Inc. as of Sep 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +12 vs. Q2 2026
- Shares held
- 946.6K
- +561.6K (+145.9%) vs. Q2 2026
- Total value
- $2.18M
- +$1.02M (+88.6%) vs. Q2 2026
- New holders
- 13
- 6 more added
- Sold out
- 1
- 1 more reduced
Compare with Q2 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INDP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q3 2026 | 21 | $2.18M |
| Q2 2026 | 9 | $1.15M |
| Q1 2026 | 6 | $128.5K |
| Q4 2025 | 4 | $93.7K |
| Q3 2025 | 5 | $57.9K |
| Q2 2025 | 5 | $3.23K |
| Q1 2025 | 19 | $377.8K |
| Q4 2024 | 20 | $539.6K |
| Q3 2024 | 18 | $750.2K |
| Q2 2024 | 21 | $1.26M |
| Q1 2024 | 17 | $1.31M |
| Q4 2023 | 19 | $1.06M |
| Q3 2023 | 16 | $1.57M |
| Q2 2023 | 15 | $1.11M |
| Q1 2023 | 15 | $1.08M |
| Q4 2022 | 18 | $838.5K |
| Q3 2022 | 18 | $1.22M |
| Q2 2022 | 17 | $1.31M |
| Q1 2022 | 17 | $6.81M |
| Q4 2021 | 15 | $10.5M |
| Q3 2021 | 15 | $4.24M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2026
Shares, value and share of portfolio for each institution holding Indaptus Therapeutics, Inc.; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 195,620 | $449.9K | 0.00% | +139,150+246.4% | Added |
| Vanguard Capital Management LLC | 135,978 | $312.7K | 0.00% | +102,326+304.1% | Added |
| Jane Street Group, LLC | 86,484 | $198.9K | 0.00% | +32,673+60.7% | Added |
| UBS Group AG | 83,363 | $191.7K | 0.00% | +82,885+17,340.0% | Added |
| Marshall Wace, LLP | 77,847 | $179.0K | 0.00% | +77,847 | New |
| Millennium Management LLC | 72,073 | $165.8K | 0.00% | +60,487+522.1% | Added |
| Vanguard Fiduciary Trust Co | 65,315 | $150.2K | 0.00% | +51,348+367.6% | Added |
| State Street Corp | 63,866 | $146.9K | 0.00% | +63,866 | New |
| Virtu Financial LLC | 34,659 | $80.0K | 0.00% | +34,659 | New |
| Jump Financial, LLC | 27,662 | $63.6K | 0.00% | +27,662 | New |
| Northern Trust Corp | 27,227 | $62.6K | 0.00% | +27,227 | New |
| ExodusPoint Capital Management, LP | 19,884 | $45.7K | 0.00% | +19,884 | New |
| Qube Research & Technologies Ltd | 14,688 | $33.8K | 0.00% | +14,688 | New |
| Goldman Sachs Group Inc | 14,143 | $32.5K | 0.00% | +14,143 | New |
| Barclays PLC | 13,723 | $31.6K | 0.00% | +13,723 | New |
| Balyasny Asset Management LLC | 12,708 | $29.2K | 0.00% | +12,708 | New |
| Morgan Stanley | 1,263 | $2.90K | 0.00% | −7,673−85.9% | Reduced |
| JPMorgan Chase & Co | 28 | $80 | 0.00% | +28 | New |
| SBI Securities Co., Ltd. | 17 | $39 | 0.00% | 00.0% | Unchanged |
| Caitong International Asset Management Co., Ltd | 2 | $5 | 0.00% | +2 | New |
| Citigroup Inc | 1 | $2 | 0.00% | +1 | New |
| HRT Financial LP | 0 | $0 | 0.00% | −206,077−100.0% | Sold out |